Importance of cyclin D1 (and CD5) detection in the diagnosis of malignant lymphomas other than mantle cell lymphoma

Česká verze

Authors: L. Plank ^1,2
Authors place of work: Ústav patologickej anatómie a Konzultačné centrum bioptickej diagnostiky ochorení krvotvorby JLF UK a UNM v Martine ¹; Martinské bioptické centrum, s. r. o. v Martine ²
Published in the journal: Čes.-slov. Patol., 47, 2011, No. 3, p. 96-100
Category: Přehledový článek

Summary

In association to our undestanding of the pathogenesis and biopsy diagnosis of mantle cell lymphoma using immunohistochemical detection of cyclin D1 expression and/or FISH detection of t(11;14)(q13;q32) all the lymphomas interfering with these factors are discussed in a form of a review. This includes a cyclin D1 negative mantle cell lymphoma, as well as other than MCL lymphomas showing positive intranuclear cyclin D1 positivity due to the changes either at transcriptional or postranscriptional levels. In addition to the MCL, the cyclin D1 positivity might be detected in the cells of hairy cell leukemia, plasmocytic lymphoma and diffuse large B-cell lymphoma. In the first two lymphomas the differential diagnostic problems usually do not arise (with exception of G3 plasmacytoma) and cyclin D1 expression might be of interess to understand better their biology, or to represent a prognostically significant factor. In contrast, cyclin D1 positivity in diffuse large B-cell lymphomas demonstrates the possible role of cyclins in the pathogenesis of this lymphoma and may lead to the problems of the differential diagnosis of aggressive variant of pleomorphic MCL (especially when occuring with CD5 positivity coexpression ). The review includes discussion related to the significance of cyclin D1 positivity and to the approach in the immunohistochemical and FISH analysis of the biopsy material.

Keywords:
lymphoma biopsy diagnosis – mantle cell lymphoma – cyclin D1 – CCND1 gene – FISH analysis

Zdroje

1. Yang WI, Zukerberg LR, Motokura T. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994; 145(1): 86–96.

2. De Boer CJ, van Krieken JHJM, Schuuring E, Kluin PM. Bcl-1/cyclin D1 in malignant lymphoma. Annals of Oncology 1997; Suppl. 2: 109–119.

3. Swerdlow SH, Campo E, Harris, N.L. et al: WHO Classification of Tumours of Heamatopoietic and Lymphoid Tissues. 4th Ed. IARC, Lyon 2008, 439 s.

4. Kodet R, Mrhalová M, Krsková L, et al. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of(11;14) (q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Archiv 2003; 442 (6): 538–547.

5. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica 2009; 94(11): 1488–1492.

6. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70(4): 1408–1418.

7. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. British J Cancer 2001; 84(2): 270–275.

8. Guo SS, Wu X, Shimoide AT, Wong J, Moatamed F, Sawicki MP. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol 2003; 179: 73–79.

9. Plevova P, Cerna D, Foretova L, et al. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer. Neoplasma 2010; 57(4): 325–332.

10. Elayat G, Selim, A-GA, Gorman P, Tomlinson I, Wells CA. Cyclin D-1 protein overexpression is not associated with gene amplification in benign and atypical apocrine lesions of the breast. Pathol Res Pract. 2010; 207 (2): 75–136.

11. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106(13): 4315–4321.

12. Metcalf RA, Zhao S, Anderson MW, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol 2010; 23(3): 420–433.

13. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, et al. Differential diagnosis of cyclin D2+ mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-polymerase chain reaction. Haematologica 2009; 94: 1595–1598.

14. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol 2008; 142: 149–165.

15. Mozos A, Royo C, Hartmann E. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94(11): 1555–1562.

16. Chen YH, Gao J, Fan G, Peterson LC. Nuclear expression of sox11 is highly associated with mantle cell lymphoma but is independent of t(11;14)(q13;q32) in non-mantle cell B-cell neoplasms. Mod Pathol 2010; 23(1): 105–112.

17. Elnenaei MO, Jadayel DM, Matutes E, et al. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies. Leuk Res 2001; 25(2): 115–123.

18. Ruchlemer R, Parry-Jones N, Brito-Babapulle V, et al. B-prolymphocytic leukaemia with t(11;14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. Br J Hematol 2004; 125(3): 330–336.

19. Bosch F, Campo E, Jares P, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Hematol 1995; 91(4): 1025–1030.

20. Miranda RN, Briggs RC, Kinney MC, et al. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia. Mod Pathol 2000; 13(12): 1308–1314.

21. Ishida F, Kitano K, Ichikawa N, et al. Hairy cell leukemia with translocation (11;20)(q13;q11) and overexpression of cyclin D1. Leuk Res 1999; 23(8): 763–765.

22. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin 1(ANXA1). Lancet 2004; 363(9424): 1869–1870.

23. Soverini S, Cavo M, Cellini C, et al. Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. Blood 2003;102: 1588–1594.

24. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005; 23(26): 6333–6338.

25. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematol Am Soc Educ Program 2005: 346–352.

26. Chiecchio L, Dagrada GP, Ibrahim AH, et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Hematologica 2009; 94(12): 1708–1713.

27. Markovic O, Marisavljevic D, Cemerikic V, et al.: Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance. Med Oncol 2004; 21(1): 73–80.

28. Hájek R, Adam Zd, Maisnar V, et al.: Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a Slovenskou myelómovou spoločností pro diagnostiku a léčbu mnohočetného myelomu. Transfuze Hematol. dnes 2009, 15, Suppl.2: 1–80.

29. Schneider A, Meyer P, DiMaio D, Fu K. Diffuse large B-cell lymphoma with both CD5 and cyclin D1 expression—a case report and review of the literature. J Hematopathol 2010; 3(4): 145–148.

30. Yamaguchi M, Seto M, Okamoto M, et al.: De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99: 815–821.

31. Rodriguez-Justo M, Huang Y, Ye H, et al. Cyclin D1-positive diffuse large B-cell lymphoma. Histopathology 2008; 52(7): 900–903.

32. Teruya-Feldstein J, Gopalan A, Moskowitz CH. CD5 negative, cyclin D1-positive diffuse large B-cell lymphoma (DLBCL) presenting as ruptured spleen. Appl Immunohistochem Mol Morphol 2009; 17(3): 255–258.

33. Plank L, Hansmann M-L, Lennert K. Centrocytic lymphoma. Am J Surg Pathol. 1993; 17(6): 638–639.